Skip to main content

Table 6 Co-morbidities in COPD and non-COPD population

From: The prevalence, burden and risk factors associated with chronic obstructive pulmonary disease in Commonwealth of Independent States (Ukraine, Kazakhstan and Azerbaijan): results of the CORE study

 

Ukraine

Kazakhstan

Azerbaijan

 

Non-COPDN = 909

COPDN = 30

p-valuea

Non-COPDN = 882

COPDN = 63

p-valuea

Non-COPDN = 898

COPDN = 35

p-valuea

Any co-morbidity

42.5%

56.7%

0.136

26.9%

50.8%

< 0.001

53.8%

74.3%

0.023

Hypertension

14.0%

40.0%

0.001

25.5%

36.5%

0.074

16.8%

34.3%

0.012

Diabetes

3.4%

6.7%

0.621

3.4%

7.9%

0.078

5.2%

8.6%

0.428

Cardiovascular disease

6.0%

26.7%

˂0.001

7.8%

22.2%

0.001

3.5%

22.9%

˂0.001

Abnormal blood lipids

4.9%

13.3%

0.062

11.7%

15.9%

0.421

1.3%

0.0%

1.000

Depression

0.7%

0.0%

1.000

0.6%

0.0%

1.000

1.9%

2.9%

1.000

Anxiety

0.2%

0.0%

1.000

0.6%

0.0%

1.000

2.6%

5.7%

0.240

Osteoporosis

0.7%

0.0%

1.000

1.6%

3.2%

0.618

0.6%

0.0%

1.000

Tuberculosis

0.2%

6.7%

0.006

2.3%

0.0%

0.391

1.4%

2.9%

1.000

Pneumonia

19.4%

36.7%

0.024

14.9%

31.7%

0.001

5.9%

17.1%

0.019

  1. atwo-sided Pearson Chi-Square test for a comparison between COPD and non-COPD populations
  2. COPD population: respondents with COPD diagnosed by spirometry (post-dose FEV1/FVC < 0.70)
  3. Non-COPD population: respondents without COPD diagnosed by spirometry (post-dose FEV1/FVC ≥ 0.70)
Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us